Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Gastric cancer in 2012

Defining treatment standards and novel insights into disease biology

Nature Reviews Clinical Oncology volume 10, pages 73–74 (2013)Cite this article

Subjects

Gastric cancer is a heterogeneous disease with almost one million new cases occurring annually worldwide. The year 2012 saw important successes and failures in gastric cancer treatment, and also novel insights into the molecular characterization of this disease, which may lead to the development of more-effective targeted therapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074–2084 (2012).

    Article  CAS  Google Scholar 

  2. Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S–1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810–1820 (2007).

    Article  CAS  Google Scholar 

  3. Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315–321 (2012).

    Article  CAS  Google Scholar 

  4. Kang, J. H. et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 30, 1513–1518 (2012).

    Article  CAS  Google Scholar 

  5. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).

    Article  CAS  Google Scholar 

  6. Waddell, T. S. et al. A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) [abstract]. J. Clin. Oncol. 30 (Suppl.), LBA4000 (2012).

    Article  Google Scholar 

  7. Lordick, F. et al. Cetuximab in combination with capecitabine and cisplatin as first-line treatment in advanced gastric cancer: randomised controlled phase III EXPAND study. Ann. Oncol. 23, ixe11 (LBA3) (2012).

    Google Scholar 

  8. Van Cutsem, E. et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J. Clin. Oncol. 30 (Suppl. 4), LBA3 (2012).

    Article  Google Scholar 

  9. Deng, N. et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61, 673–684 (2012).

    Article  CAS  Google Scholar 

  10. Oliner, K. S. et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer [abstract]. J. Clin. Oncol. 30 (Suppl.), 4005 (2012).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, Surrey, UK

    Elizabeth C. Smyth & David Cunningham

Authors
  1. Elizabeth C. Smyth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Cunningham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth C. Smyth.

Ethics declarations

Competing interests

D. Cunningham declares he receives research funding from Amgen, AstraZeneca, Celgene, Merck-Serono, Sanofi, Roche. He also provides uncompensated advise for Roche and Amgen. E. C. Smyth declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smyth, E., Cunningham, D. Defining treatment standards and novel insights into disease biology. Nat Rev Clin Oncol 10, 73–74 (2013). https://doi.org/10.1038/nrclinonc.2012.228

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.228

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer